Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Spectrum Disorders Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

NCT04559529
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam (LEV) 500 mg, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jun 26, 2026, 2:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Knowledge and Perception of Smoking Risks/Consequences

NCT00686101
View directory record Official record
Conditions
Cigarette Smoking, Schizophrenia
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

NCT01242371
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Probiotic Supplement, Identical-appearing Placebo
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis

NCT02155699
View directory record Official record
Conditions
Attenuated Psychosis Syndrome
Interventions
Exercise 1, Exercise 2
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
16 Years to 24 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jun 26, 2026, 2:46 PM EDT
Recruiting Not applicable Interventional

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

NCT05389787
View directory record Official record
Conditions
Schizophrenia, Cerebellar Function, Condition
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness

NCT02663349
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Psychotic Disorders
Interventions
Social Cognition and Intervention Training
Behavioral
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Jun 26, 2026, 2:46 PM EDT
Not yet recruiting Not applicable Interventional

BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis

NCT07417904
View directory record Official record
Conditions
Violence Risk, Early Psychosis
Interventions
BRAVE (Behavioral Response Against Violence Engagement), Treatment As Usual (TAU)
Behavioral · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional

A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition

NCT00525304
View directory record Official record
Conditions
Schizophrenia
Interventions
Self-management program for chronic illness
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Pimozide Augmentation for Clozapine Partial Response

NCT00374244
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimozide, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

NCT02013609
View directory record Official record
Conditions
MDD
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for Paranoia in Schizophrenia

NCT01704833
View directory record Official record
Conditions
Paranoid Delusions
Interventions
Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jun 26, 2026, 2:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

NCT03077347
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

CAE for Poorly Adherent Individuals With Schizophrenia

NCT06061952
View directory record Official record
Conditions
Schizophrenia
Interventions
Customized Adherence Enhancement for Schizophrenia (CAE-S), Enhanced Treatment as Usual (eTAU)
Behavioral · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional Results available

Weight Management Program for Patients With First Episode Psychosis

NCT05207982
View directory record Official record
Conditions
Diet, Healthy, Psychotic Disorders
Interventions
Family Based weight management program
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
14 Years to 26 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia

NCT00601224
View directory record Official record
Conditions
Schizophrenia
Interventions
Social cognition and interaction training (SCIT), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

NCT01567943
View directory record Official record
Conditions
Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jun 26, 2026, 2:46 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

NCT03437668
View directory record Official record
Conditions
Schizophrenia
Interventions
WSE, Placebo Oral Tablet
Drug
Lead sponsor
Chengappa, K.N. Roy, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jun 26, 2026, 2:46 PM EDT
Active, not recruiting Not applicable Interventional

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

NCT05756855
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder, Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
adapted behavioral intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
16 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive

NCT01927276
View directory record Official record
Conditions
Schizophrenia
Interventions
Gluten Free Flour, Wheat Flour
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jun 26, 2026, 2:46 PM EDT
Not yet recruiting Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

NCT06923891
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/Trospium
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682
View directory record Official record
Conditions
Schizophrenia
Interventions
Anti-inflammatory Combination Therapy, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

NCT00053703
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 19 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Jun 26, 2026, 2:46 PM EDT